Irreversible airway obstruction in asthma

Current Allergy and Asthma Reports

Volumn 9, Issue 2, 2009, Pages 168-173

  Boulet, Louis Philippe ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADAM 33 PROTEIN; ADAM PROTEIN; BRONCHODILATING AGENT; CORTICOSTEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ASTHMA; ATOPY; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION; HUMAN; INCOMPLETE REVERSIBILITY OF AIRWAY OBSTRUCTION; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG PARENCHYMA; OBESITY; OCCUPATIONAL ASTHMA; OCCUPATIONAL EXPOSURE; ONSET AGE; PATIENT COMPLIANCE; RESPIRATORY AIRFLOW; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SEX DIFFERENCE;

AIRWAY OBSTRUCTION; ASTHMA; HUMANS; RISK FACTORS; SMOKING;

EID: 60349085076     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-009-0025-2     Document Type: Review

References (70)

1. Global Initiative for Asthma (GINA): GINA Report, Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org/ Guidelineitem.asp??l1=2&l2=1&intId=60. Accessed January 5, 2009.
2. WeDzel SE: Asthma: defining of the persistent adult phenotypes. Lancet 2006, 368:804-813.
3. Boulet LP, Becker A, Bérubé D, et al.: Summary of recommendations from the Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999, 161:S1-S12.
4. Brown PJ, Greville HW, Finucane KE: Asthma and irreversible airflow obstruction. Thorax 1984, 39:131-136.
5. Boulet LP, Turcotte H, Turcot O, Chakir J: Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med 2003, 97:739-744.
6. Boulet L, Belanger M, Carrier G: Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am J Respir Crit Care Med 1995, 152:865-871.
7. Ulrik CS, Backer V: Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999, 14:892-896.
8. ten Brinke A: Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 2008, 8:63-69.
9. ten Brinke A, Zwinderman AH, Sterk PJ, et al.: Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001, 164:744-748.
10. Guerra S, Sherrill DL, Kurzius-Spencer M, et al.: The course of persistent airflow limitation in subjects with and without asthma. Respir Med 2008, 102:1473-1482.
11. Hudon C, Turcotte H, Laviolette M, et al.: Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Ann Allergy Asthma Immunol 1997, 78:195-202.
12. Loren ML, Leung PK, Cooley RL, et al.: Irreversibility of obstructive changes in severe asthma in childhood. Chest 1978, 74:126-129.
13. Vonk JM, Jongepier H, Panhuysen CI, et al.: Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003, 58:322-327.
14. Lee JH, Haselkorn T, Borish L, et al.: Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007, 132:1882-1889.
15. Bergeron C, Boulet LP: Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006, 129:1068-1087.
16. Finucane KE, Greville HW, Brown PJ: Irreversible airfl ow obstruction. Evolution in asthma. Med J Aust 1985, 142:602-604.
17. Gelb AF, Zamel N: Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000, 162:1778-1782.
18. Boulet L, Becker A, Bowie D,Aet al.: Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. Can Respir J 2006, 13(Suppl A):5-47.
19. Barnes PJ, Ito K, Adcock IM: Corticosteroid resistance in chronic obstructive pulmonary disease: Inactivation of histone deacetylase. Lancet 2004, 363:731-733.
20. Bumbacea D, Campbell D, Nguyen L, et al.: Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004, 24:122-128.
21. Jang AS, Lee JH, Park SW, et al.: Risk factors related to fi xedairway obstruction in patients with asthma after antiasthma treatment. Ann Allergy Asthma Immunol 2007, 99:408-412.
22. Covar RA, Spahn JD, Murphy JR, Szefler SJ: Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med 2004, 170:234-241.
23. van Veen I, ten Brinke A, Sterk PJ, et al.: Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008, 32:344-349.
24. Fabbri LM, Romagnoli M, Corbetta L, et al.: Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:418-424.
25. ten Brinke A, Zwinderman AH, Sterk PJ, et al.: "Refractory" eosinophilic airway inflammation in severe asthma: Effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004, 170:601-605.
26. Jeffery PK: Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Exp Allergy 1999, 29(Suppl 2):14-26.
27. Mauad T, Dolhnikoff M: Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008, 14:31-38.
28. Lazaar AL, Panettieri RA Jr: Is airway remodeling clinically relevant in asthma? Am J Med 2003, 115:652-659.
29. Ward C, Johns DP, Bish R, et al.: Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma. Am J Respir Crit Care Med 2001, 164:1718-1721.
30. Tillie-Leblond I, De Blic J, Jaubert F, et al.: Airway remodeling is correlated with obstruction in children with severe asthma. Allergy 2008, 63:533-541.
31. Boulet LP, Lemiere C, Archambault F, et al.: Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest 2006, 129:661-668.
32. Humbles AA, Lloyd CM, McMillan SJ, et al.: A critical role for eosinophils in allergic airways remodeling. Science 2004, 305:1776-1779.
33. Lemiere C, Ernst P, Olivenstein R, et al.: Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006, 118:1033-1039.
34. Tschumperlin DJ, Drazen JM: Chronic effects of mechanical force on airways. Annu Rev Physiol 2006, 68:563-583.
35. Holgate ST, Davies DE, Lackie PM, et al.: Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000, 105:193-204.
36. Jongepier H, Boezen HM, Dijkstra A, et al.: Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004, 34:757-760.
37. Morgan WJ, Stern DA, Sherrill DL, et al.: Outcome of asthma and wheezing in the fi rst 6 years of life: Follow-up through adolescence. Am J Respir Crit Care Med 2005, 172:1253-1258.
38. Stern DA, Morgan WJ, Wright AL, et al.: Poor airway function in early infancy and lung function by age 22 years: A non-selective longitudinal cohort study. Lancet 2007, 370:758-764.
39. Sears MR, Greene JM, Willan AR, et al.: A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003, 349:1414-1422.
40. Phelan PD, Robertson CF, Olinsky A: The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 2002, 109:189-194.
41. Marossy AE, Strachan DP, Rudnicka AR, Anderson HR: Childhood chest illness and the rate of decline of adult lung function between ages 35 and 45 years. Am J Respir Crit Care Med 2007, 175:355-359.
42. de Marco R, Marcon A, Jarvis D, et al.: Prognostic factors of asthma severity: A 9-year international prospective cohort study. J Allergy Clin Immunol 2006, 117:1249-1256.
43. Rasmussen F, Taylor DR, Flannery EM, et al.: Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: A longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002, 165:1480-1488.
44. Bai TR, Vonk JM, Postma DS, Boezen HM: Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007, 30:452-456.
45. O'Byrne PM, Pedersen S, Lamm CJ, et al.; START Investigators Group: Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009, 179:19-24.
46. Gautrin D, Boulet LP, Boutet M, et al.: Is reactive airways dysfunction syndrome a variant of occupational asthma? J Allergy Clin Immunol 1994, 93:12-22.
47. Anees W, Moore VC, Burge PS: FEV1 decline in occupational asthma. Thorax 2006, 61:751-755.
48. Lemiere C, Boulet LP: CiAarette smoking and asthma: a dangerous mix. Can Respir J 2005, 12:79-80.
49. Thomson NC, Chaudhuri R, Livingston E: Asthma and cigarette smoking. Eur Respir J 2004, 24:822-833.
50. St-Laurent J, Bergeron C, Page N, et al.: Influence of smoking on airway inflammation and remodelling in asthma. Clin Exp Allergy 2008, 38:1582-1589.
51. Chalmers GW, Macleod KJ, Little SA, et al.: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002, 57:226-230.
52. Chaudhuri R, Livingston E, McMahon AD, et al.: Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003, 168:1308-1311.
53. Goksor E, Amark M, Alm B, et al.: The impact of pre- and post-natal smoke exposure on future asthma and bronchial hyper-responsiveness. Acta Paediatr 2007, 96:1030-1035.
54. Lange P, Parner J, Vestbo J, et al.: A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998, 339:1194-1200.
55. Burrows B, Bloom JW, Traver GA, Cline MG: The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987, 317:1309-1314.
56. ten Brinke A, van Dissel JT, Sterk PJ, et al.: Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001, 107:449-454.
57. Boulet LP, Des Cormiers A: The Aink between obesity and asthma: a Canadian perspective. Can Respir J 2007, 14:217-220.
58. Boulet LP, Hamid Q, Bacon SL, et al.: Symposium on obesity and asthma-November 2, 2006. Can Respir J 2007, 14:201-208.
59. Parameswaran K, Todd DC, Soth M: Altered respiratory physiology in obesity. Can Respir J 2006, 13:203-210.
60. Miranda C, Busacker A, Balzar S, et al.: Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004, 113:101-108.
61. Backman KS, Greenberger PA, Patterson R: Airways obstruction in patients with long-term asthma consistent with 'irreversible asthma'. Chest 1997, 112:1234-1240.
62. Barnes PJ: MecDanisms in COPD: differences from asthma. Chest 2000, 117:10S-14S.
63. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003, 22:470-477.
64. Hansen EF, Phanareth K, Laursen LC, et al.: Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:1267-1271.
65. Panizza JA, James AL, Ryan G, et al.: Mortality and airflow obstruction in asthma: A 17-year follow-up study. Intern Med J 2006, 36:773-780.
66. Mauad T, Bel EH, Sterk PJ: Asthma therapy and airway remodeling. J Allergy Clin Immunol 2007, 120:997-1009.
67. Dijkstra A, Vonk JM, Jongepier H, et al.: Lung function decline in asthma: Association with inhaled corticosteroids, smoking and sex. Thorax 2006, 61:105-110.
68. Green RH, Brightling CE, McKenna S, et al.: Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002, 360:1715-1721.
69. Jayaram L, Pizzichini MM, Cook RJ, et al.: Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations. Eur Respir J 2006, 27:483-494.
70. Cox G, Thomson NC, Rubin AS, et al.: Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007, 356:1327-1337.